Condition: Gastrointestinal Cancer · Sponsor: DualityBio Inc.
This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.
This description comes directly from the study's public registry record.
Zhaochuan Wang · 4123279868 · zhaochuan.wang@dualitybiologics.com
Yuanyuan Sun · yuanyuan.sun@dualitybiologics.com
Always discuss trial participation with your own doctor first.
| USA05-0 | Port Saint Lucie, Florida, United States | Recruiting |
| USA02-0 | Grand Rapids, Michigan, United States | Recruiting |
| USA01-0 | Huntersville, North Carolina, United States | Recruiting |
| USA03-0 | Cincinnati, Ohio, United States | Recruiting |
| AUS02-0 | Randwick, New South Wales, Australia | Recruiting |
| AUS03-0 | South Brisbane, Queensland, Australia | Recruiting |
| AUS01-0 | Nedlands, Western Australia, Australia | Recruiting |
| CHN01-0 | Beijing, China | Recruiting |
| CHN04-0 | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07263594